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Abstract
Opiates are some of the most effective pain relief medications available for pa-
tients suffering from cancer and surgery-related pain. Despite the affordability
and effectiveness of these medications, access to opiates is highly geographically
variable. Pain researchers have attributed geographic variation to various factors
including the fear of opioid addiction, diversion of legal opiods to the underground
market and pharmaceutical industry influences. However, the extent to which
there is inequity in untreated cancer and surgery-related pain is unknown. To help
opioid investigators study these questions, we designed a tool, the Opioid Atlas,
for exploring data on legal opioid consumption, by country and time, collected by
the International Narcotics Control Board. Our design borrows ideas from the data
visualization and multivariate statistics communities, especially the principles of
linking and dimensionality reduction. Our work is relevant to policymakers and
pain researchers who wish to systematically assess country-level factors that con-
tribute to differences in opioid access for patients with cancer and surgery-related
pain. The Opioid Atlas, and the code behind it, is freely available with an open
source license.
1 Introduction
Opiates are low cost and effective, an example of high-value healthcare. Despite this fact, access
to pain relief medications for patients suffering from cancer and surgery-related pain is limited and
highly geographically variable Knaul et al. [2015a,b]. Experts have suggested that international
opiate policy reform is necessary to improve pain management and reduce unnecessary suffering,
especially at the end-of-life Berterame et al. [2016]. However, our scientific understanding of the
factors that lead to disparities are limited to anecdotal evidence and healthcare surveys conducted on
a relatively small sample of clinicians in a few countries Laxmaiah Manchikanti and Vallejo [2011].
Our work aimed to achieve three goals. The first was to obtain and systematically analyze a dataset
describing trends in global opioid distribution. The second was to develop a transformation of
the dataset that would facilitate its use by other investigators. Finally, we aimed to create a data
visualization tool that a domain expert could use to explore patterns in global opioid access data
across times, countries, and drugs.
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In this paper, we describe our process, from data acquisition to tool production, and high-
light several new insights into global opioid distribution that were enabled by the Opioid Atlas
(https://krisrs1128.github.io/OpioidAtlas/). Our R code for data processing, all analyses, and visu-
alizations are freely available on github (https://github.com/krisrs1128/OpioidAtlas) under an open
sources license.
2 Methods
2.1 Data Sources
Our global opioid distribution dataset was obtained from the International Narcotics Control Board
(INCB). The INCB is an independent and quasi-judicial monitoring body for the implementation of
the United Nations international drug control conventions. It was established in 1968 in accordance
with the Single Convention on Narcotic Drugs, 1961 Organization [March 30, 1961]. Every year,
they publish technical reports on the state of opioid consumption, including tables of raw data.
This data is spatiotemporal, with one sample for each country for every year from 1989 to 2013,
with an extra dimension for drug type. We note a few nonstandard characteristics. First, there are
many zeros, mostly associated with smaller countries with no access to certain drugs or incomplete
reporting, which tend to occur earlier in the collection period and over consecutive years. Second,
there is a dramatic difference in scale between the largest and smallest consumers – plotting all series
on the same y-axis range is not informative. Third, the different classes of drugs are not directly
comparable, because some have stronger medical potency than others. Hence, we transformed each
series into ”morphine-equivalent” kilograms per year for Disease Control [2016]. Finally, there
are many departures from smoothness, across time, space, and drugs, in the sense that dramatic
dips and spikes occur within individual countries time series, scales can shift substantially between
neighboring countries, and countries can have variable access to the different opioids.
2.2 Exploratory Techniques
The Opioid Atlas is designed to give representations of the data that facilitate comparisons across
times, countries, and drugs. Our approach is to simplify the navigation across a large collection
of related time series. To this end, we borrow ideas from the data visualization and multivariate
statistics communities, especially the principles of linking and dimensionality reduction.
2.2.1 Linking
In the visualization community, linking refers to tying together different representations of a dataset
in one display Buja et al. [1996], Becker and Cleveland [1987]. Our first view links a choropleth
of opioid access with time series of opioid consumption for individual countries. The linking is
implemented through mouseovers: when the user hovers over a country, the time series display
transitions to reflect abundance across all drugs for the hovered-over country. When the user selects
a year and an opioid, the choropleth and time series update to reflect the new specification. This
linking makes it easy to compare time series across neighboring countries.
In the next few views, we generalize this linking idea by defining our own similarities across coun-
tries. This makes it easier to compare countries that have similarly shaped series but which are not
necessarily geographically close.
2.2.2 Cognostics
In the first generalization, we adapt the idea of cognostics, an early exploratory data analysis tech-
nique for comparing large collections of scatterplots Tukey [1977], Hafen et al. [2013]. A cognostic
is a single summary statistic for a scatterplot – correlation or regression slope, for example – which
can be used to order the otherwise unwieldy collection. For the Opioid Atlas, we precomputed a
collection of cognostics – the difference between the last and first measured point and the maximum
one year increase, for example – for each country and each drug. We then generate a dot-plot of
these cognostics and link each dot to the time series view for that country. This allows the user to
see both typical and outlier values for each cognostic, as well as the associated original series.
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2.2.3 Multidimensional Scaling
In the second generalization, we use multidimensional scaling (MDS), a method from multivariate
statistics, to organize the individual time series. In multidimensional scaling, we define an abstract
distance between samples and generate a scatterplot where the distances between points approx-
imate the original abstract distance Kruskal [1964]. In the Opioid Atlas, our abstract distance is
the Euclidean distance between cube-rooted time series. The resulting MDS scatterplot provides
an alternative to the world map in the first view. As in this first view, we link individual points to
their associated time series. This facilitates comparison between series that are shaped similarly,
according to raw Euclidean distance.
2.2.4 Local Regressions
In our final generalization, we define a new map according to overall and trends in access to opioids.
The goal is to define an MDS-like scatterplot directly in terms of quantities that are interesting to
domain experts. Towards this, we define a ”local” average and slope for each series and each time
point. For each fixed year, we display a scatterplot of countries and drugs with respect to these
statistics. As before, each point is linked with the associated time series view. Changing years
transitions points on the scatterplot to reflect updated statistics. We define local averages and slopes
using local ridge regressions Cleveland and Devlin [1988], calling fitted values at each timepoint
local averages, and the associated slopes the local slopes. In this view, it is easy to see groups of
countries with rapid increases and decreases in access across short time periods, while maintaining
context about overall access to opioids.
3 Results
Here we highlight two illustrative examples of how we used the Opioid Atlas to identify interesting
trends in global opioid distribution. Our examples highlight the types of relationship that are of
interest to opioid investigators and would not be revealed by traditional opioid distribution analysis
and reporting methods.
We used our first generalization to prioritize our search for temporal trends of interest at the country
level. One trend was discovered by identifying Asian countries with rapidly increasing levels of
oxycodone consumption and reviewing their linked time series. Figure 1 shows the linked time
series for Hong Kong, which shows dramatic increases in total annual opioid consumption after
the transfer of sovereignty from the United Kingdom to the People’s Republic of China in 1997.
Also illustrated in Hong Kong’s time series, was evidence of ”toggling.” Opioid class toggling is
characterized by a decrease in one opioid class due to an increased consumption of opioid class,
within the same duration. An example demonstrating opioid class toggling between oxycodone and
pethidine is shown on the right of Figure 1.
(a) Sovereignity (b) Drug Toggling
Figure 1: Temporal opioid consumption trends in Hong Kong. Annual consumption trends before
and after the transfer of sovereignty from the UK to China (1997) appear on the left; an example of
toggling between oxycodone and pethidine in 2010 appears on the right.
For two opioid classes, oxycodone and pethidine, we used our second generalization, based on
MDS, to automatically group European and African countries with similar consumption patterns.
Figure 2 shows the country-level “clusters” we found for the opioid oxycodone, in red, and the
opioid pethidine, in blue. Our linked country-level time series revealed that red countries located in
the upper right side of the chart, (e.g., Denmark, Germany, Ireland), were associated with increased
oxycodone consumption, and exclusively European. The linked time series of countries that in the
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upper middle of the chart in blue (e.g., Zambia, Uganda, Namibia, Ghana, and Lithuania) showed
increased pethidine consumption; although they include some European countries such as Lithuania
and Latvia, most are African.
Figure 2: Opioid consumption clusters in Europe and Africa with linked Danish time series on the
right.
Lastly, for the European countries associated with rapid increase in oxocodone consumption in Fig-
ure 2, there are two specific findings that may warrant consideration by opioid investigators. Specif-
ically, most European countries with a rapid increase in oxycodone consumption showed a rapid
decrease for the opioids pethidine, morphine and hydrocodone (i.e., toggling). Notably, Denmark
was the only country with a visual decrease in oxycodone consumption shortly after 2007, when
three of the drug manufacturer’s executives pleaded guilty in federal court to criminal charges that
they misled regulators, doctors and patients about the drugs risk of addiction and its potential to be
abused Meier [2007].
4 Discussion
In order to identify the best strategies to improve pain management for cancer and surgery patients,
a better understanding of country and regional consumption patterns, pharmaceutical industry influ-
ences, and sociopolitical factors that impact country-level consumption are needed. The Opioid At-
las was developed to facilitate description of historical patterns. Based on the INCB’s global opioid
distribution data from 1989-2013, our tool allows for comparisons across time, regions, countries,
and opioid classes.
Our results show how the atlas can be used to identify relationships of interest to opioid investigators.
We highlight trends in country-level opiate consumption that are not fully explained by population
size, gross national product or healthcare access more generally. For example, the dramatic increase
in opioids observed in the five year period after Hong Kong’s sovereignty was transferred from the
United Kingdom to the People’s Republic of China, an observation of interest to investigators who
have hypothesized an association between low opioid use and British colonization. We also highlight
and example of drug-class toggling – i.e., in the absence of new randomized clinical trial evidence or
a regulatory recall, the replacement of one class for another could suggest possible pharmaceutical
industry influences, which would not be seen by analyzing opiate consumption in aggregate.
It is important to note that our tool is only the first step of a scientific inquiry process that must
involve further studies to provide a more certain explanation for opioid disparities. Additional limi-
tations of our work include the quality of the INCB data, which can differ by country and reporting
year.
5 Conclusion
We introduced the Opioid Atlas, a website of visualizations that can be used to better describe the
history of opioid consumption globally, and described the process and principles behind its design.
Our work is a case study in blending ideas from data visualization and multivariate statistics in order
to build a tool adapted to a specific domain problem. Our focus on linking and interactivity comes
from the visualization literature, while our application of dimensionality reduction methods has a
distinctly statistical flavor.
We have discussed patterns in the consumption of opioids both to demonstrate the the ease of nav-
igation enabled by this tool and to suggest its usefulness in practice. By making our data and code
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publicly available, we attempt to reflect best practices in open, reproducible research. By making
this data more easily explorable, we hope to inspire a data-centered discussion, both among domain
experts and across the general public, of disparities in access to pain relief.
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